CRISPR Therapeutics AG's latest marketcap:
As of 07/04/2025, CRISPR Therapeutics AG's market capitalization has reached $4.79 B. According to our data, CRISPR Therapeutics AG is the 3430th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 4.79 B |
| Revenue (ttm) | 37.68 M |
| Net Income (ttm) | -385,657,000 |
| Shares Out | 91.75 M |
| EPS (ttm) | -4.52 |
| Forward PE | 0.00 |
| Ex-Dividend Date | n/a |
| Earnings Date | 08/04/2025 |
CRISPR Therapeutics AG's yearly market capitalization.
| Date | Market Cap | Change (%) | Global Rank |
|---|---|---|---|
| 07/04/2025 | $4.79 B | 32.83% | 3430 |
| 12/31/2024 | $3.36 B | -32.44% | 3998 |
| 12/29/2023 | $4.97 B | 56.24% | 2879 |
| 12/30/2022 | $3.18 B | -45.12% | 3854 |
| 12/31/2021 | $5.8 B | -46.39% | 2848 |
| 12/31/2020 | $10.82 B | 221.74% | 1528 |
| 12/31/2019 | $3.36 B | 126.76% | 3219 |
| 12/31/2018 | $1.48 B | 53.95% | 4843 |
| 12/29/2017 | $963.1 M | 19.42% | 7290 |
| 12/30/2016 | $806.5 M | 7435 |
Company Profile
About CRISPR Therapeutics AG
CRISPR Therapeutics AG is a pioneering gene editing company dedicated to developing transformative gene-based medicines for serious human diseases. The company leverages its proprietary CRISPR/Cas9 platform, a revolutionary technology that enables precise alterations to genomic DNA sequences.
Key Therapeutic Programs
The company’s diverse portfolio spans multiple disease areas, including:
- Hemoglobinopathies: Focused on treating transfusion-dependent beta-thalassemia and severe sickle cell disease (SCD).
- CAR T Cell Therapies: Developing investigational programs targeting solid tumors and autoimmune diseases.
- In Vivo Gene Editing: Addressing cardiovascular diseases by disrupting validated targets like angiopoietin-like protein 3 and lipoprotein.
- Type 1 Diabetes (T1D): Advancing hypoimmune stem cell-derived therapies.
Lead Product Candidate
CASGEVY is the company’s flagship ex vivo CRISPR/Cas9 gene-edited cell therapy. It is designed to treat patients with hemoglobinopathies by editing hematopoietic stem and progenitor cells to produce elevated levels of fetal hemoglobin in red blood cells.
Strategic Partnerships
CRISPR Therapeutics collaborates with industry leaders to accelerate innovation, including partnerships with:
- Vertex Pharmaceuticals Incorporated
- Nkarta, Inc.
- Capsida Biotherapeutics
Company Background
Founded in 2013, CRISPR Therapeutics AG is headquartered in Zug, Switzerland, and continues to lead advancements in gene editing technologies.
Frequently Asked Questions
-
What is CRISPR Therapeutics AG's (CRSP) current market cap?As of 07/04/2025, CRISPR Therapeutics AG (including the parent company, if applicable) has an estimated market capitalization of $4.79 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does CRISPR Therapeutics AG (CRSP) rank globally by market cap?CRISPR Therapeutics AG global market capitalization ranking is approximately 3430 as of 07/04/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.